What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 24326326.
- Also identified by DOI 10.1136/bjophthalmol-2013-303844 and PMC identifier 4033205.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Anti-vascular endothelial growth factor (VEGF) therapy has revolutionised the treatment of retinal disease, and appears to be very safe. Nevertheless, there are several lines of evidence that imply that small doses of these agents could potentially have a systemic effect. The clinical significance of these systemic effects remains unclear, but further study is indicated.
Medical subject headings
- Angiogenesis Inhibitors
- Retinal Diseases
- Vascular Endothelial Growth Factor A